Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983099 | 0.84 | RAB9A (0.51) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10094592 | 0.79 | MAPK10 (0.60) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL31220854 | 0.78 | MEN1 (0.50) | RAB9ANPC1ALDH1A1KDM4EMAPT | |
| SCHEMBL31220873 | 0.75 | RAB9A (0.61) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL27463110 | 0.73 | KDM4E (0.54) | RAB9ANPC1RAPGEF4ALDH1A1KDM4E | |
| SCHEMBL12589876 | 0.73 | MKNK1 (0.42) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL1334869 | 0.73 | RAPGEF4 (0.74) | RAB9ANPC1RAPGEF4ALDH1A1MAPT | |
| SCHEMBL30320262 | 0.73 | RAPGEF4 (0.74) | RAB9ANPC1RAPGEF4ALDH1A1MAPT | |
| SCHEMBL24173204 | 0.73 | NPC1 (0.46) | RAB9ANPC1RAPGEF4ALDH1A1HPGD | |
| SCHEMBL26186665 | 0.73 | RAB9A (0.46) | RAB9ANPC1RAPGEF4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-22 | — | — | US | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RAB9A 2644/4885NPC1 3590/4885RAPGEF4 3417/4885 |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | RAB9A 3652/4885NPC1 2295/4885RAPGEF4 1549/4885 |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RAB9A 2644/4885NPC1 3590/4885RAPGEF4 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.